$FBLG News
Last published 3w ago
- 3w agoFBLGFibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual MeetingPR NewswireFSdC Spheroids Preserved Disc Height Better Than Any Other Fibroblast-Based Approach Tested in a 12-Week Rabbit Model of Degenerative Disc DiseaseHOUSTON, Oct. 19, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG)
- 4w agoFBLGFibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal DiscsPR NewswireAccepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Media to Regenerate Cartilage and Improve the Condition of Degenerated and Aged
- 1mo agoFBLGFibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the BodyPR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on...
- 1mo agoFBLGFibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic ActivityPR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending...
- 1mo agoFBLGFibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific OfficerPR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending...
- 2mo agoFBLGFibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound HealingPR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on...
- 2mo agoFBLGFibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned MediaPR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending...
- 2mo agoFBLGFibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical TrialPR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending...
- 2mo agoFBLGFibroBiologics Regains Compliance with Nasdaq Trading RulesPR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending...
- 2mo agoFBLGFibroBiologics Appoints Leigh Steinberg to Board of DirectorsPR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on...
- 2mo agoFBLGFibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc DiseasePR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on...
- 2mo agoFBLGFibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative JointsPR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on...
- 3mo agoFBLGFibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing IsletsPR NewswirePatent has potential for applications beyond diabetes, including other cell and tissue transplantation proceduresHOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a
- 3mo agoFBLGFibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of CartilagePR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending...
- 3mo agoFBLGFibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care CandidatePR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on...
- 4mo agoFBLGFibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of DirectorsPR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on...
- 4mo agoFBLGFibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical TrialPR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on...
- 4mo agoFBLGFibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual ConferencePR NewswireFibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on...
- 4mo agoFBLGFibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesPR NewswireFibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending...
- 4mo agoFBLGFibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesPR NewswireFibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending...
- 4mo agoFBLGFibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound HealingGlobeNewswireHOUSTON, June 22, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 4mo agoFBLGFibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot UlcersGlobeNewswireHOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 5mo agoFBLGFibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot UlcersGlobeNewswireHOUSTON, June 03, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 5mo agoFBLGFibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual MeetingGlobeNewswireHOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 5mo agoFBLGFibroBiologics Files Patent Application for Oral Administration of Fibroblast TherapeuticsGlobeNewswireHOUSTON, May 18, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of
- 6mo agoFBLGFibroBiologics Advancing Development of a Fibroblast Treatment for HantavirusGlobeNewswireHOUSTON, May 11, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development of
- 6mo agoFBLGFibroBiologics CEO Issues Letter to ShareholdersGlobeNewswireHOUSTON, May 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 6mo agoFBLGFibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce ScarringGlobeNewswireHOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 6mo agoFBLGFibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical TrialGlobeNewswireHOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 6mo agoFBLGFibroBiologics Reports Q1 2026 Financial Results and Provides Corporate UpdateGlobeNewswireHOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 6mo agoFBLGFibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026GlobeNewswireHOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 6mo agoFBLGFibroBiologics Compliant with All Nasdaq Listing RequirementsGlobeNewswireHOUSTON, April 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 7mo agoFBLGFibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and ImmunityGlobeNewswireHOUSTON, April 10, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the
- 7mo agoFBLGFibroBiologics Announces Closing of $3 Million Public OfferingGlobeNewswireHOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the
- 7mo agoFBLGFibroBiologics Announces Pricing of $3 Million Public OfferingGlobeNewswireHOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the
- 7mo agoFBLGFibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical TrialGlobeNewswireHOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 7mo agoFBLGFibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price RequirementGlobeNewswireHOUSTON, March 25, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 8mo agoFBLGFibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid TechnologyGlobeNewswireHOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 8mo agoFBLGFibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot UlcersGlobeNewswireHOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 8mo agoFBLGFATEMESOLGVNCell Therapies Moving From Lab to Factory Floor, and the Stocks Behind ThemPR NewswireUSANewsGroup.com News Commentary — The global cell therapy market is projected to surpass $8.2 billion in 2026, driven by a wave of clinical...
- 8mo agoFBLGFibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of OsteoporosisGlobeNewswireHOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the
- 8mo agoFBLGFibroBiologics to Present at the BIO Investment & Growth SummitGlobeNewswireHOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 8mo agoFBLGFibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswirePlanning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026 Improved balance sheet through multiple direct offerings; completed payments of
- 8mo agoFBLGFibroBiologics Granted Extension by Nasdaq to Regain ComplianceGlobeNewswireHOUSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the
- 9mo agoFBLGFibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown UniversityGlobeNewswireHOUSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the
- 9mo agoFBLGFibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for CachexiaGlobeNewswireHOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the
- 9mo agoFBLGFibroBiologics to Present at the DealFlow Discovery ConferenceGlobeNewswireHOUSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 10mo agoFBLGFibroBiologics CEO Issues Letter to ShareholdersGlobeNewswireHOUSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of
- 10mo agoFBLGFibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment ConferenceGlobeNewswireHOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the
- 10mo agoFBLGFibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc DiseaseGlobeNewswireHOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of